ArcaMax

It's estimated that 7.2 million folks in the U.S. have Alzheimer's disease (AD); it's the sixth leading cause of death among folks ages 65 and older. But new studies offer the promise of significant progress in the treatment of AD.

The first, published in Alzheimer's & Dementia, found that taking the diabetes-control medication Jardiance (empagliflozin) significantly lowered brain-tangle-related tau in cerebrospinal fluid. It also changed blood flow in key brain regions. The study also found that intranasal insulin improved performance on tests that detect early memory and thinking changes. It also increased the structural integrity of white matter connections and changed blood flow patterns in brain areas related to memory. Both medications also boosted immune function and reduced inflammation. Wow!

The second study, done in mice, reveals a possible way to open up the waste-clearing channels in the brain to allow clumps and tangles of amyloid-beta plaques to be cleared out. Within hours of the first injection of nanoparticles, the mice flushed almost 45% of the tangles from their brain. This doesn't mean it will be as effective in people -- but it's a great first test!

Additionally, the findings of the randomized AMBAR studies revealed that therapeutic plasma exchange (TPE) reversed cognitive function in early AD patients. See my summary of all the research on TPE at LifepanEdge.com.

And if you're dealing with cognition issues, tune into the dozens of ways you can stay young in mind and body that are available through our AI-based (and very refined) coaching program at 4YOUngveity.com.

Health pioneer Michael Roizen, M.D., is chief wellness officer emeritus at the Cleveland Clinic and author of four No. 1 New York Times bestsellers. Check out his latest, "The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow," and find out more at www.4YOUngevity.com. Email your health and wellness questions to Dr. Mike at questions@4YOUngevity.com.

(c)2023 Michael Roizen, M.D.

Distributed by King Features Syndicate, Inc.

(c) 2025 Michael Roizen, M.D. Distributed by King Features Syndicate, Inc.